Snapshot from Apr 21, 2026 at 07:00 UTC. For live data and tracking: View Live
Entities / Centessa Pharmaceuticals
Company

Centessa Pharmaceuticals

Tracked across 2 events · 38 articles · First seen Feb 12, 2026 · Last active Apr 16, 2026

Sentiment
0
Attention
2
Events
2
Relationships
1
Live sentiment trends, attention charts, and prominence tracking available on the NewsDesk Dashboard
Events (2)
2 10
Business
Nxera Pharma receives US$3M milestone payment
Centessa Pharmaceuticals achieved an early development milestone for its investigational drug ORX489, triggering a US$3 million payment to Nxera Pharma. This indicates progress in their drug development pipeline.
Feb 12, 2026 · 9 articles
0 -10
Business
Monteverde & Associates PC Investigates Multiple M&A Deals
Centessa Pharmaceuticals plc is under investigation by Monteverde & Associates PC concerning its sale to Eli Lilly and Company, with shareholders set to receive $38.00 per share in cash and a contingent value right.
Mar 30, 2026 · 29 articles
Key Actions (2)
80 Monteverde & Associates PC launched investigation into proposed transactions Centessa PharmaceuticalsMonteverde & Associates PC...
70 Centessa Pharmaceuticals sold to Eli Lilly and CompanyMonteverde & Associates PC...
Relationships (1)
Nxera Pharma research collaboration partner ↔ Centessa Pharmaceuticals Nxera Pharma and Centessa Pharmaceuticals have a research collaboration agreemen
NEWSDESK
Track Centessa Pharmaceuticals live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.